fbpx

Psychedelic Options for Addressing Addiction

Log In To Watch The Recording

*Exclusive for members.

Thursday, April 28th at 5 pm Pacific, 8 pm Eastern >> Log In To Watch The Recording >>

Watch The EXCLUSIVE Panel Discussion For Members Of The Psychedelic Medicine Association:

Psychedelic Options for Addressing Addiction

Panel Moderator:

Lynn Marie Morski, MD, JD

President - Psychedelic Medicine Association

Panelists:

Evan Wood, MD, PhD, FASAM, FRCPC

Chief Medical Officer at Numinus

Dr. Evan Wood has published over 650 peer-reviewed scientific articles and made major contributions to the establishment of innovative policy and therapeutic programs. Early in his career, Dr. Wood’s research contributed to revision of international guidelines for the treatment and prevention of HIV infection among persons who use drugs. Subsequently, he led efforts that have contributed to the regulation of adult cannabis use in Canada, the establishment of supervised injecting facilities as a standard of care for overdose prevention in Canada, and clinical therapeutic guidelines for a range of substance use disorders. Dr. Wood developed one of North America’s largest addiction medicine eduction programs and has been a Tier 1 Canada Research Chair and Professor of Medicine. As Numinus’ Chief Medical Officer, Dr. Wood is responsible for planning clinical research, assisting with protocol development, and clinical strategy within the organization.

Dr. Rick Barnett, PsyD

Co-Founder of Psychedelic Society of Vermont

Dr. Rick is a licensed clinical psychologist, licensed addictions counselor, and holds a Master's degree in clinical psychopharmacology. He founded and is CEO of CARTER, Inc (501c3 organization to address addiction), runs a private group general mental health and addiction group practice, and is co-founder of the Psychedelic Society of Vermont. Rick has been trained by MAPS for MDMA-Assisted Psychotherapy and completed a year-long psychedelic research and treatment program through the California Institute for Integral Studies. Rick offers Ketamine-Based Psychotherapy to select patients in his private practice. He has also serves on several boards with Vermont State Government, the Vermont Psychological Association, and the American Psychological Association. In addition, Rick has been in recovery from addiction for nearly 30 years and is an active advocate for recovery from addictions.

Kevin Franciotti, MA, LAC

Therapist & Psychedelic Program Director at Ballen Medical & Wellness

Kevin Franciotti is a Master’s-level therapist and Licensed Addiction Counselor, writer, and recovery advocate based in Denver. He is a former advisory board member for Project New Day foundation’s inaugural community-engaged public health project, Psychedelics in Recovery: Outreach and Service, focusing on support for mutual aid groups with members who integrate psychedelic experiences for ongoing addiction recovery. In 2011, Kevin underwent treatment for opioid use disorder with ibogaine, a drug derived from the iboga shrub indigenous to west-central Africa. He has previously written about his experience in various publications, including New Scientist magazine and TheFix.com.

At the heart of so many physical and mental health conditions lies the issue of addiction. Opioids, tobacco, and alcohol are just a few of the substances causing both mental suffering and physical harm to patients. 

Fortunately, psychedelic medicines have shown much promise in the area of treating addiction, both directly and indirectly – via addressing the trauma that so often lies at the root of addictive patterns.

In the area of direct addiction treatment, we’ve seen promising research from psilocybin for tobacco cessation, MDMA for alcohol use disorder, and ibogaine for opioid use disorder.

So while many health professionals are concerned about recommending psychedelic therapies to their patients for fear that psychedelics are addictive, the truth of the matter is that many of these substances are anti-addictive – so we were very excited to have a panel of guests to help elucidate some of how psychedelic therapies have been shown to help with the challenge of unraveling addiction disorders.

We were honored to have expert panelists on this month’s webinar to cover:

  • The research into different psychedelic medicines’ potential in treating addiction disorders
  • The role therapy plays in addressing addiction with psychedelic medicines
  • How patients prepare for and integrate after psychedelic treatments for addiction

…and much more!

As always, there was ample time for audience Q & A, so make sure you watch to the end!

You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.